Science and Laboratory

Our research-driven genomics laboratory specialises in gastrointestinal and gynaecological disease, applying advanced sequencing technologies, bioinformatics, and data science to uncover molecular mechanisms and accelerate translational breakthroughs. By integrating DNA mutation profiling, methylation mapping, microbiome analysis, and hologenomics, we deliver high-resolution insights that bridge discovery to precision medicine.

Using high-throughput NGS pipelines, we identify both common oncogenic mutations and novel variants. From targeted panels to whole-genome sequencing, every variant undergoes rigorous quality control and expert interpretation, providing clinically actionable mutation landscapes.

DNA methylation profiling reveals epigenetic fingerprints of disease and tumour origin. Leveraging enzymatic conversion and array-based methods, we identify stable, disease-specific methylation biomarkers for early detection, prognosis, and patient stratification.

We characterise gastrointestinal and vaginal microbiomes using 16S rRNA sequencing and metagenomics, linking microbial dysbiosis to inflammation, genomic instability, and cancer development. With microbes implicated in 60% of diseases and 20% of malignancies, microbiome integration is central to our diagnostics.

We pioneer hologenomics, integrating host and microbial genomes from a single biospecimen to view the host-microbe system as one entity. This holistic approach identifies biomarker clusters, risk factors, and therapeutic targets, enabling diagnostic tests that capture both human and microbial signals in a single assay.